Patient Support

Study emphasizes role in bridging research and development and commercial/marketing functions.

Digital twins allow the industry to integrate sustainable practices and supply chain efficiency solutions while ensuring patient safety.

ClearNetwork will be available for a plan sponsor’s list of covered generic, branded, and specialty drugs across 65,000 retail pharmacies in the Express Scripts network.

New initiative highlights importance of a collaborative approach that allows patients to share their insights and contribute value to studies.

Financial commitment further strengthens IntegriChain’s platform as a source for pharma manufacturers' commercialization and market access goals.

Conference session discusses the drivers, practical considerations, success factors, and landscape for next-generation pharmacy innovation.

Bill Roth provides insight as to how where chief commercial officers and access leaders can plan for a profitable product lifecycle.

While there are still hurdles to overcome along the way, home healthcare could deliver better patient-centered cancer care, providing improved patient outcomes, enhanced quality of life, and reduced strain on resources.

Direct Relief executive provides more information about the company.

Kirsch discusses the complexity of the drugs and the verification process, along with Eversana’s new platform, ACTICS eAccess.

A look into ways to approach change management using three factors.

These programs can negatively impact patients trying to reach their deductible.

Pharmaceutical product distributor continues goal of delivering safe and affordable medication to patients.

Company brings aboard former Pfizer exec as life sciences COO in effort to help further improve patient outcomes.

Collaboration to focus on digital therapeutics.

Program designed to aid life science organizations in improving go-to-market strategy.

While an option for financial assistance, patients should consider the challenges.

Creating a user-centric approach that harnesses both digital tools and behavioral science is key to getting—and maintaining—patients on therapy, and improving clinical, financial, and, ultimately, brand-success outcomes for pharma manufacturers.

Offer potential to improve patient care, including in medication adherence.

Choosing the right pharmacy to administer the program involves a number of factors.

The importance of industry, as it moves forward, in focusing on patient-centered care and prioritizing patient needs across the supply chain.

Agreement is expected to help improve the medication delivery process for patients.

The Medicare Part D cap in 2025 won’t solve patients’ need for financial assistance.

Company delivers additional supply chain logistics and distribution experience to specialty pharmaceutical market.

The platform agnostic CGT hub hopes to streamline the path-to-care process, by providing physicians and patient services teams with visibility across the therapy development and delivery process.

Although there is no ‘one size fits all’ solution, the process is influenced by factors such as lifestyle stage, competitive outlook, and market constraints.

Innovation and investment in advancing lifesaving therapies for pediatric patients to the commercial stage remains a daunting task, but rapid advances today in modeling and simulation are reducing the hurdles for drugmakers.

With the rapid rise of the specialty drug market, manufacturers are increasingly relying on new advances used by patient hubs to boost their levels of patient engagement.

Deciphering the different "technology-first” and “technology-enabled” patient support programs.

How personalized interventions can help boost the omnichannel experience for patient hubs—and drive engagement and impact adherence in outcomes.